Bayer/Regeneron plan Eylea combination trials for wet AMD
This article was originally published in Scrip
Executive Summary
Bayer and Regeneron Pharmaceuticals are to launch a new clinical trial of their marketed anti-VEGF therapy Eylea (aflibercept) in combination with a new antibody to platelet derived growth factor receptor beta (PDGFR-beta), as a treatment for the ophthalmic condition wet age-related macular degeneration.